BLTE logo

BLTE Belite Bio, Inc

NASDAQ Capital Market · Biotechnology · Healthcare

$127.38
-23.64 (-15.65%)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials,…

Market Cap: $5.17Bbelitebio.com

Price

No data yet.

Social Signal Score

32
5d
40
1 mentions
—
30d
30
3 mentions
—
60d
24
6 mentions
—
90d
34
15 mentions
—
news: 12 · rss: 3

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 0Sell 0Strong Sell 0
Avg price target$250.8+96.9%
Low $206Median $245High $303
Current Consensus

Revenue

$0.00
$0.00
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-2.18
$-2.27–$-2.09
6 analysts
FY2026
$-3.03
$-3.24–$-2.77
7 analysts
FY2027
$1.46
$-5.80–$11.49
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Yu-Hsin Lin
Sector
Healthcare
Industry
Biotechnology
Employees
41
Beta
-1.19
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
207.88
belitebio.com